A. Nademanee

发表

An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era.

R. Gascoyne, L. Sehn, Zheng Zhou, 2014, Blood.

Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma.

A. Nademanee, J. Dipersio, G. Bridger, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma.

A. Nademanee, J. Dipersio, J. Kaufman, 2009, Blood.

Approach to Hodgkin's lymphoma in the new millennium

A. Nademanee, H. Fung, 2002, Hematological oncology.

A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome.

A. Nademanee, A. Krishnan, M. Slovak, 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

High Body Mass Index in Elderly Patients With DLBCL Treated With Rituximab-Containing Therapy Compensates for Negative Impact of Male Sex.

Zheng Zhou, A. Rademaker, L. Gordon, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Non-Hodgkin's lymphomas, version 4.2014.

J. Byrd, R. Advani, J. Vose, 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

New Genomic Model Integrating Clinical Factors and Gene Mutations to Predict Overall Survival in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP

Rebecca Ottesen, Raju Pillai, Jasmine Zain, 2018, Blood.

Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease.

A. Nademanee, A. Krishnan, G. Somlo, 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic stem cell transplantation for thalassemia major

A. Nademanee, A. Krishnan, A. Raubitschek, 2008 .

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

A. Nademanee, P. Stiff, V. Bachanova, 2015, The Lancet.

Brentuximab vedotin and its use in the treatment of advanced Hodgkin's lymphoma.

A. Nademanee, L. Nikolaenko, 2020, Future oncology.

Anti-CD25 radioimmunotherapy with BEAM autologous hematopoietic cell transplantation conditioning in Hodgkin lymphoma

A. Nademanee, J. Bading, J. Wong, 2021, Blood advances.

Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report.

A. Nademanee, J. Dipersio, J. Kaufman, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phase II Study of Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BCNU, Etoposide, Cytarabine, and Melphalan for Non-Hodgkin Lymphoma: The Role of Histology.

A. Nademanee, A. Krishnan, S. Forman, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phase II Study of Yttrium-90 Ibritumomab Tiuxetan Plus High Dose BEAM for Non-Hodgkin Lymphoma: The Role of Histology

A. Nademanee, A. Krishnan, S. Forman, 2017 .

Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma.

A. Nademanee, S. Forman, Robert Chen, 2012, Blood.

Rapid development of HPV-mediated oropharyngeal squamous cell carcinoma in the setting of immune suppression following autologous stem cell transplantation for Hodgkin lymphoma

D. Weisenburger, A. Nademanee, Huiqing Wu, 2017 .

Allogeneic bone marrow transplantation for high-risk acute lymphoblastic leukemia during first complete remission

A. Nademanee, M. Amylon, N. Chao, 1991 .

Role of hematopoietic stem cell transplantation for advanced-stage diffuse large cell B-cell lymphoma-B.

A. Nademanee, S. Forman, 2006, Seminars in hematology.

relapsed non-Hodgkin lymphoma by autologous stem cell transplantation in patients with poor-risk or combination with high-dose etoposide and cyclophosphamide followed A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in

David D. Smith, A. Nademanee, A. Krishnan, 2013 .

A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma.

David D. Smith, A. Nademanee, A. Krishnan, 2005, Blood.

Results of high-dose therapy and autologous bone marrow/stem cell transplantation during remission in poor-risk intermediate- and high-grade lymphoma: international index high and high-intermediate risk group.

A. Nademanee, J. Niland, G. Somlo, 1997, Blood.

High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with analysis of prognostic factors.

A. Nademanee, G. Somlo, G. M. Schmidt, 1995, Blood.

Efficacy of peripheral blood stem cell transplantation

A. Nademanee, 1994, Journal of clinical apheresis.

Hepatitis C and B-Cell Lymphoma

A. Nademanee, A. Molina, A. Kashyap, 1998, Annals of Internal Medicine.

Fractionated total body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 99 patients with acute leukemia in first complete remission.

Eileen, A. Nademanee, J. Niland, 1993, Blood.

Solid C ancers A fter B one M arrow T ransplantation

A. Nademanee, J. Niland, A. Krishnan, 2001 .

Non-Hodgkin's Lymphomas, version 3.2012.

J. Byrd, R. Advani, J. Vose, 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

Clinical and ultrasonic evaluation of spleen size during peripheral blood progenitor cell mobilization by filgrastim: results of an open-label trial in normal donors.

A. Nademanee, H. Lazarus, R. Gingrich, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Protective Effect of HLA-DPB1 Mismatch Remains Valid in Reduced-Intensity Conditioning Unrelated Donor Hematopoietic Cell Transplantation

A. Nademanee, S. Forman, D. Snyder, 2019, Bone Marrow Transplantation.

The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone.

A. Nademanee, J. Niland, G. Somlo, 1995, Blood.

Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease.

A. Nademanee, J. Niland, M. Amylon, 1993, The New England journal of medicine.

Detrimental effect of natural killer cell alloreactivity in T-replete hematopoietic cell transplantation (HCT) for leukemia patients.

A. Nademanee, Marcia M. Miller, S. Forman, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Safety and efficacy of upfront plerixafor + G‐CSF versus placebo + G‐CSF for mobilization of CD34+ hematopoietic progenitor cells in patients ≥60 and <60 years of age with non‐Hodgkin's lymphoma or multiple myeloma

A. Nademanee, J. Dipersio, P. Stiff, 2013, American journal of hematology.

Second time a charm? Remobilization of peripheral blood stem cells with plerixafor in patients who previously mobilized poorly despite using plerixafor as a salvage agent

A. Nademanee, A. Krishnan, Shan Yuan, 2013, Transfusion.

Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.

A. Nademanee, J. Dipersio, G. Bridger, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Comparative Trial of AMD3100 (Plerixafor)+G-CSF vs. G-CSF+Placebo for Mobilization in Multiple Myeloma (MM) Patients for Autologous Hematopoietic Stem Cell (aHSC) Transplantation.

A. Nademanee, J. Dipersio, G. Bridger, 2007 .

A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation.

J. Vose, A. Nademanee, J. Fay, 1998, Blood.

Consolidation with Nivolumab and Brentuximab Vedotin after Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma

A. Nademanee, L. Kwak, Y. Nieto, 2020 .

Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse.

A. Nademanee, P. Stiff, V. Bachanova, 2018, Blood.

Double-hit Signature with TP53 Abnormalities Predicts Poor Survival in Patients with Germinal Center Type Diffuse Large B-cell Lymphoma Treated with R-CHOP

W. Chan, D. Weisenburger, D. Scott, 2020, Clinical Cancer Research.

Non-Hodgkin's lymphomas, version 2.2014.

J. Byrd, R. Advani, J. Vose, 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

High-dose chemo/radiotherapy and autologous bone marrow or stem cell transplantation for poor-risk advanced-stage Hodgkin's disease during first partial or complete remission.

A. Nademanee, J. Niland, A. Krishnan, 1999, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016.

J. Byrd, R. Advani, J. Vose, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Non-Hodgkin’s Lymphomas, Version 4.2014: Clinical Practice Guidelines in Oncology

J. Byrd, R. Advani, J. Vose, 2014 .

Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015.

J. Byrd, R. Advani, J. Vose, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

Bone marrow transplantation for myelodysplastic and myeloproliferative syndromes.

P. Bierman, A. Nademanee, R. Krance, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma

A. Nademanee, P. Frankel, S. Forman, 2015, Haematologica.

Autologous transplantation for transformed non-Hodgkin lymphoma using an yttrium-90 ibritumomab tiuxetan conditioning regimen.

A. Nademanee, A. Krishnan, S. Forman, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.

A. Nademanee, G. M. Schmidt, D. Snyder, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Longitudinal assessment of hematopoietic abnormalities after autologous hematopoietic cell transplantation for lymphoma.

A. Nademanee, A. Krishnan, M. Slovak, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Non-Hodgkin's lymphomas, version 1.2013.

J. Byrd, R. Advani, J. Vose, 2013, The Journal of the National Comprehensive Cancer Network.

Transformed non‐Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database

L. Gordon, A. LaCasce, Allison Crosby-Thompson, 2013, British journal of haematology.

Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab.

A. Nademanee, L. Kwak, I. Aldoss, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Primary cutaneous gamma-delta T-cell lymphoma with marked pagetoid epidermotropism shortly after allogeneic stem cell transplantation.

A. Nademanee, Qin Huang, Marnelli A. Bautista-Quach, 2013, Clinical lymphoma, myeloma & leukemia.

NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019.

R. Advani, J. Vose, L. Gordon, 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

Safety Analysis of Brentuximab Vedotin from the Phase III AETHERA Trial in Hodgkin Lymphoma in the Post-Transplant Consolidation Setting.

A. Nademanee, P. Stiff, J. Sweetenham, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD Prophylaxis.

A. Nademanee, S. Forman, A. Salhotra, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic hematopoietic cell transplantation in non-Hodgkin's lymphomas.

A. Nademanee, I. Aldoss, 2015, Cancer treatment and research.

Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma.

A. Nademanee, A. Krishnan, S. Forman, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ALLOGENEIC BONE MARROW TRANSPLANTATION FOR ACUTE LYMPHOBLASTIC LEUKEMIA DURING FIRST COMPLETE REMISSION

L. R. Hill, A. Nademanee, D. Findley, 1987, Transplantation.

HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia.

A. Nademanee, J. Klein, M. Horowitz, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides.

A. Nademanee, D. Arber, S. Forman, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphoma.

David D. Smith, A. Nademanee, A. Krishnan, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse

A. Nademanee, P. Stiff, V. Bachanova, 2015 .

Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation

A. Nademanee, J. Fridey, L. Weiss, 2007, Transfusion.

Transplantation for non-Hodgkin lymphoma

A. Nademanee, 2009, Expert review of hematology.

Plerixafor to the rescue: boosting peripheral blood stem cell mobilization in patients previously treated with hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone/methotrexate, cytarabine (Hyper-CVAD) chemotherapy

A. Nademanee, A. Salhotra, Shan Yuan, 2014, Leukemia & lymphoma.

Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies.

A. Nademanee, J. Niland, M. Amylon, 1997, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A phase II trial 90y-ibritumomab tiuxetan in combination with reduced intensity regimen of fludarabine (flu) and melphalan (mel) followed by allo-HCT in patients with refractory B-cell lymphoma.

A. Nademanee, S. Forman, A. Raubitschek, 2012 .

High-Dose Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Patients with Poor-Risk or Relapsed Non-Hodgkin's Lymphoma (NHL)

David D. Smith, A. Nademanee, A. Krishnan, 2017 .

Non-Hodgkins Lymphoma (NHL) by Autologous Stem Cell Transplant in Patients with Poor-Risk or Relapsed Combination with High-Dose Etoposide and Cyclophosphamide Followed A Phase I/II Trial of High-Dose Yttrium 90 ibritumomab tiuxetan in

David D. Smith, A. Nademanee, A. Krishnan, 2013 .

Radioimmunotherapy for stem cell transplantation in non-Hodgkin's lymphoma: in pursuit of a complete response.

J. Vose, A. Nademanee, C. Gisselbrecht, 2009, The Oncologist.

Plerixafor plus granulocyte colony-stimulating factor improves the mobilization of hematopoietic stem cells in patients with non-Hodgkin lymphoma and low circulating peripheral blood CD34+ cells.

A. Nademanee, J. Dipersio, G. Calandra, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma.

A. Nademanee, J. Dipersio, G. Bridger, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial.

A. Nademanee, L. Kwak, Y. Nieto, 2022, The Lancet. Haematology.

A phase I study in adults of clofarabine combined with high-dose melphalan as reduced-intensity conditioning for allogeneic transplantation.

A. Nademanee, P. Frankel, S. Forman, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

NCCN guidelines® insights chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017: Featured updates to the NCCN guidelines

J. Byrd, R. Advani, J. Vose, 2017 .

NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017.

J. Byrd, R. Advani, J. Vose, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial.

A. Nademanee, J. Niland, M. Amylon, 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma. A California Cancer Consortium Study.

A. Nademanee, D. Gandara, P. Frankel, 2007 .

Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study.

A. Nademanee, Yan Liu, L. Robison, 2005, Blood.

Fractionated total-body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 94 patients with chronic myelogenous leukemia in chronic phase.

A. Nademanee, M. Amylon, R. Negrin, 1994, Blood.

Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization

A. Nademanee, J. Liesveld, G. Bridger, 2010, Bone Marrow Transplantation.

Treatment of allosensitized patients receiving allogeneic transplantation

A. Nademanee, S. Forman, R. Champlin, 2021, Blood advances.

Preemptive ganciclovir administration based solely on asymptomatic pulmonary cytomegalovirus infection in allogeneic bone marrow transplant recipients: long-term follow-up.

A. Nademanee, J. Niland, J. Zaia, 1995, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study.

A. Nademanee, L. Robison, S. Bhatia, 2007, Blood.

Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prevention of acute graft-vs.-host disease: effect on chronic graft-vs.-host disease and long-term survival.

A. Nademanee, J. Niland, M. Amylon, 1999, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation.

R. Advani, A. Nademanee, J. Friedberg, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Non-Hodgkin's Lymphomas, version 3.2012: Featured updates to the NCCN guidelines

J. Byrd, R. Advani, J. Vose, 2012 .

High-dose therapy and autologous hematopoietic cell transplantation in peripheral T cell lymphoma (PTCL): analysis of prognostic factors.

A. Nademanee, S. Forman, K. Gaal, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control

A. Nademanee, S. Forman, D. Senitzer, 2011, Leukemia & lymphoma.

The Impact of Disease Status on the Outcome of High-Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT) for Peripheral T-Cell Lymphoma (PTCL).

A. Nademanee, A. Krishnan, S. Forman, 2006 .

Monocytoid b‐cell lymphoma clinicopathologic study of 21 cases of a unique type of low‐grade lymphoma

A. Nademanee, K. Sheibani, C. Winberg, 1988, Cancer.

Non-Hodgkin's lymphomas, version 1.2013.

J. Byrd, R. Advani, J. Vose, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

Interleukin-2 after autologous stem-cell transplantation for adult patients with acute myeloid leukemia in first complete remission.

A. Nademanee, J. Niland, A. Krishnan, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A. Nademanee, W. Wen, D. Weisdorf, 2000, Blood.

A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation.

J. Vose, A. Nademanee, J. Dipersio, 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Fractionated total body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 99 patients with acute leukemia in first complete remission

A. Nademanee, M. Amylon, R. Negrin, 1993 .

Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database.

L. Gordon, A. LaCasce, A. Vanderplas, 2012, Blood.

Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab

L. Gordon, A. LaCasce, A. Vanderplas, 2013, Cancer.

The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial.

A. Nademanee, R. Fisher, M. Leblanc, 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Hematopoietic Cell Transplantation for Hodgkin Disease

P. Bierman, A. Nademanee, 2016 .

Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation

A. Nademanee, J. Rossi, L. Kwak, 2018, Journal of Hematology & Oncology.

Interleukin-2 A fter A utologous S tem-Cell T ransplantation f or Adult P atients W ith A cute M yeloid L eukemia i n F irst Complete R emission

A. Nademanee, J. Niland, A. Krishnan, 2003 .

Effect of HLA class II gene disparity on clinical outcome in unrelated donor hematopoietic cell transplantation for chronic myeloid leukemia: the US National Marrow Donor Program Experience.

A. Nademanee, A. Begovich, C. Kollman, 2001, Blood.

Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the National Marrow Donor Program

A. Nademanee, S. Davies, C. Kollman, 2000 .

Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the national marrow donor program.

A. Nademanee, S. Davies, C. Kollman, 2000, Blood.

Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia.

A. Nademanee, J. Niland, M. Amylon, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation.

A. Nademanee, J. Fay, R. Storb, 1998, Blood.

Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma.

A. Nademanee, A. Krishnan, S. Forman, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin's lymphoma.

A. Nademanee, J. Niland, A. Krishnan, 2000, Clinical lymphoma.

Analysis of hematopoietic cell transplants using plasma-depleted cord blood products that are not red blood cell reduced.

A. Nademanee, D. Gjertson, S. Forman, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Analysis of 120 pediatric patients with nonmalignant disorders transplanted using unrelated plasma‐depleted or ‐reduced cord blood

A. Nademanee, S. Forman, R. Chow, 2012, Transfusion.

Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for High-Risk Acute Lymphoblastic Leukemia.

A. Nademanee, R. Champlin, S. Solomon, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Reduced-intensity allogeneic stem cell transplantation for patients whose prior autologous stem cell transplantation for hematologic malignancy failed.

A. Nademanee, A. Krishnan, G. Somlo, 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Long-term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation From Unrelated Donor Using Tacrolimus/Sirolimus-based GvHD Prophylaxis: Impact of HLA Mismatch

A. Nademanee, S. Forman, D. Snyder, 2020, Transplantation.

Transplant Survivor Study functional status of long-term survivors: report from the Bone Marrow Late mortality after allogeneic hematopoietic cell transplantation and

A. Nademanee, L. Robison, S. Bhatia, 2011 .

Phase-2 Trial of an Intensified Conditioning Regimen for Allogeneic Hematopoietic Cell Transplant for Poor-Risk Leukemia

A. Nademanee, J. Wong, S. Forman, 2010, Bone Marrow Transplantation.

Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network.

A. Nademanee, M. Horowitz, Juan Wu, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Post-thaw washing prior to transplantation of Umbilical Cord Blood units (UCB) that were depleted of plasma but not of red blood cells

A. Nademanee, D. Gjertson, R. Chow, 2006 .

Effect of Post-Thaw Washing Prior to Transplantation of Umbilical Cord Blood Units (UCB) That Were Depleted of Plasma but Not of Red Blood Cells.

A. Nademanee, D. Gjertson, R. Chow, 2005 .

Clinical Outcome of Hematopoietic Stem Cell Transplantation (HSCT) Using Plasma Depleted Umbilical Cord Blood Units (UCB) That Were Not Depleted of Red Blood Cells Prior to Cryopreservation.

A. Nademanee, D. Gjertson, R. Chow, 2005 .

Hematopoietic Stem Cell Transplantation (HSCT) for Benign Indications Using Umbilical Cord Blood Units (UCB) That Were Depleted of Plasma, but Not of Red Blood Cells.

A. Nademanee, D. Gjertson, R. Chow, 2005 .

Thymoma-associated severe aplastic anemia treated with surgical resection followed by allogeneic stem-cell transplantation.

A. Nademanee, F. Grannis, S. Lau, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Engraftment and outcomes following autologous stem cell transplantation in Hodgkin lymphoma patients mobilized with plerixafor

A. Nademanee, A. Dagis, Shan Yuan, 2017, Hematological oncology.

23: A Novel Method to Reduce Rates of Extensive Chronic GvHD (cGvHD) without Increased Relapse for Cord Blood Transplant

A. Nademanee, D. Gjertson, J. Kurtzberg, 2008 .

Fractionated total body irradiation and high dose cyclophosphamide: a preparative regimen for bone marrow transplantation for patients with hematologic malignancies in first complete remission

L. R. Hill, P. Bierman, A. Nademanee, 1988, Blut: Zeitschrift für die Gesamte Blutforschung.

Autologous stem cell transplantation for HIV-associated lymphoma.

A. Nademanee, A. Krishnan, J. Zaia, 2001, Blood.

diffuse large B-cell lymphoma treated in the rituximab era An enhanced International Prognostic Index (NCCN-IPI) for patients with

R. Gascoyne, L. Sehn, Zheng Zhou, 2014 .

High-dose chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy during first complete remission in adult patients with poor-risk aggressive lymphoma: a pilot study.

A. Nademanee, K. Margolin, G. M. Schmidt, 1992, Blood.

Poxvirus Vectored Cytomegalovirus Vaccine to Prevent Cytomegalovirus Viremia in Transplant Recipients

A. Nademanee, I. Aldoss, S. Forman, 2020, Annals of Internal Medicine.

R‐CHOP with iodine‐131 tositumomab consolidation for advanced stage diffuse large B‐cell lymphoma (DLBCL): SWOG S0433

A. Nademanee, M. Kaminski, J. Friedberg, 2014, British journal of haematology.

Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B-cell Lymphoma.

A. Nademanee, D. Maloney, P. Armand, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Immunohistochemi-NCCN Diffuse Large B-Cell Lymphoma Version 1 . 2016 Clinical Practice Guidelines in Oncology

J. Byrd, R. Advani, J. Vose, 2016 .

Implant-associated primary anaplastic large-cell lymphoma with simultaneous involvement of bilateral breast capsules.

D. Weisenburger, A. Nademanee, Wengang Chen, 2013, Clinical breast cancer.

Phase III Study Comparing Methotrexate and Tacrolimus ( Prograf , FK 506 ) With Methotrexate and Cyclosporine for Graft-Versus-Host Disease Prophylaxis After HLA-Identical Sibling Bone Marrow Transplantation

A. Nademanee, J. Fay, R. Storb, 1998 .

Conditional Survival and Cause-specific Mortality after Autologous Hematopoietic Cell Transplantation for Hematological Malignancies

A. Nademanee, A. Krishnan, S. Bhatia, 2012, Leukemia.

Allogeneic bone marrow transplantation for high risk non-hodgkin's lymphoma during first complete remission

P. Bierman, A. Nademanee, S. Forman, 1987, Blut.

Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.

A. Nademanee, J. Leonard, Bihong T. Chen, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Matched-cohort analysis of autologous hematopoietic cell transplantation with radioimmunotherapy versus total body irradiation-based conditioning for poor-risk diffuse large cell lymphoma.

A. Nademanee, A. Krishnan, S. Forman, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease.

A. Nademanee, J. Niland, K. Gould, 1996, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation.

W. Chan, D. Weisenburger, A. LaCasce, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation.

A. Nademanee, N. Kröger, B. Storer, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma

A. Nademanee, S. Forman, J. Rosenthal, 2011, Annals of Hematology.

Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.

A. Nademanee, G. Marcucci, S. Forman, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

High dose therapy and autologous stem cell transplantation for human immunodeficiency virus‐associated non‐Hodgkin lymphoma in the era of highly active antiretroviral therapy

A. Nademanee, A. Krishnan, J. Zaia, 2000, Cancer.

Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphoma.

A. Nademanee, S. Forman, T. Siddiqi, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A Phase II Trial of Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis in HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation

A. Nademanee, G. Marcucci, I. Aldoss, 2020 .

The Use of Sirolimus Combined with Tacrolimus and Low-Dose Methotrexate Is Effective in Preventing Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation.

A. Nademanee, S. Forman, D. Senitzer, 2006 .

Lack of benefit of central nervous system prophylaxis for diffuse large B‐cell lymphoma in the rituximab era

L. Gordon, A. LaCasce, A. Vanderplas, 2012, Cancer.

Does follicularity in large cell lymphoma predict outcome after autologous stem cell transplantation?

A. Nademanee, A. Krishnan, M. Slovak, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A phase II study of sirolimus, tacrolimus, and rabbit anti-thymocyte globulin as graft-versus-host prophylaxis after unrelated-donor peripheral blood stem cell transplant

A. Nademanee, S. Forman, D. Senitzer, 2012, Bone Marrow Transplantation.

Treatment with AMD3100 in Multiple Myeloma or Non-Hodgkin’s Lymphoma Patients to Increase the Number of Peripheral Blood Stem Cells When Given with a Mobilizing Regimen of Chemotherapy and G-CSF.

A. Nademanee, J. Liesveld, L. Akard, 2004 .

Graft-Versus-Host Disease Associated Post-operative Complications After Pelvic Reconstructive Surgery: A Case Report

A. Nademanee, M. Sadeghi, Christopher P. Chung, 2022, International Journal of Cancer Management.

Plerixafor (Mozobi ® )Plus G-CSF Is More Effective Than Placebo Plus G-CSF in Mobilizing CD34+ Hematopoietic Stem Cells in Patients with Multiple Myeloma Who Have Low (<20 cells/μl) Peripheral Blood CD34+ Cell Count.

A. Nademanee, J. Dipersio, P. Stiff, 2009 .

Diffuse Large B-Cell Lymphoma Version 1.2016.

J. Byrd, R. Advani, J. Vose, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Iron Overload is Associated with Delayed Engraftment and Increased Non-Relapse Mortality in Recipients of Umbilical Cord Blood Hematopoietic Cell Transplantation.

A. Nademanee, G. Marcucci, I. Aldoss, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Understanding Caregiver Quality of Life in Caregivers of Hospitalized Older Adults With Cancer

A. Nademanee, S. Pal, S. Forman, 2019, Journal of the American Geriatrics Society.

Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Chemotherapy in Mantle Cell Lymphoma Patients Is Associated with Higher Rates of Hematopoietic Progenitor Cell Mobilization Failure despite Plerixafor Rescue.

A. Nademanee, I. Aldoss, S. Forman, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma.

A. Nademanee, D. Gandara, P. Frankel, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radiation for diffuse large B‐cell lymphoma in the rituximab era: Analysis of the National Comprehensive Cancer Network lymphoma outcomes project

L. Gordon, A. LaCasce, Allison Crosby-Thompson, 2015, Cancer.

Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma.

W. Chan, D. Weisenburger, A. Nademanee, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Incidence, Method and Covariates of Central Nervous System (CNS) Prophylaxis for Diffuse Large B-Cell Lymphoma In the National Comprehensive Cancer Network (NCCN) Lymphoma Database

L. Gordon, A. LaCasce, A. Vanderplas, 2010 .

Fractionated total-body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 94 patients with chronic myelogenous leukemia in chronic phase.

A. Nademanee, M. Amylon, R. Negrin, 1994, Blood.

Polymyositis as a Manifestation of Chronic Graft‐Versus‐Host Disease

A. Nademanee, J. Niland, J. Ben-Ezra, 1996, Medicine.

positive acute lymphoblastic leukemia Bone marrow transplantation for patients with Philadelphia chromosome

P. Bierman, A. Nademanee, S. Forman, 2011 .

A Comparison of Beam and Yttrium 90 Ibritumomab Tiuxetan (Zevalin®) in Addition to Beam (Z-BEAM) in Older Patients Undergoing Autologous Stem Cell Transplant (ASCT) for B-Cell Lymphomas: Impact of Radioimmunotherapy on Transplant Outcomes.

A. Nademanee, A. Krishnan, S. Forman, 2006 .

Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma

A. Nademanee, J. Radford, S. Ramsey, 2016, British journal of haematology.

Comparison of referring and final pathology for patients with T‐cell lymphoma in the National Comprehensive Cancer Network

L. Gordon, A. LaCasce, Allison Crosby-Thompson, 2014, Cancer.

Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using 90Y-Ibritumomab Tiuxetan (Zevalin) in Combination With Fludarabine and Melphalan in Patients With High-Risk B-Cell Non-Hodgkin's Lymphoma.

A. Nademanee, S. Forman, R. Spielberger, 2023, Clinical lymphoma, myeloma & leukemia.

Incidence and Risk Factors of CMV Reactivation after Haploidentical Hematopoietic Cell Transplantation Using High-Dose Post-Transplant Cyclophosphamide - Possible Role of Donor KIR Genotypes

A. Nademanee, G. Marcucci, I. Aldoss, 2018, Blood.

Response-adapted anti-PD1 based salvage therapy for Hodgkin lymphoma with nivolumab +/- ICE (NICE).

A. Nademanee, L. Kwak, S. Rosen, 2022, Blood.

Comparative Analysis of Autologous Hematopoietic Cell Transplantation with Radioimmunotherapy (RIT) Based Conditioning Versus Total Body Irradiation (TBI) for High-Risk Diffuse Large Cell Lymphoma (DLCL): Toxicity and Efficacy

A. Nademanee, A. Krishnan, S. Forman, 2010 .

90Y-Ibritumomab Tiuxetan (Zevalin®) in Combination with High-Dose Therapy (HDT) Followed by Autologous Stem Cell Transplant (ASCT) May Improve Survival in Patients with Poor-Risk Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL): Results of a Retrospective Comparative Analysis.

A. Nademanee, A. Krishnan, S. Forman, 2006 .

Reduced Intensity Conditioning (RIC) with Rituximab Yields Excellent Outcomes after Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Relapsed Follicuar Lymphoma (FL): A Phase II Multicenter Trial from the Blood and Marrow Transplant Network (BMT CTN 0701)

A. Nademanee, M. Horowitz, Juan Wu, 2014 .

Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomized trial by the Southwest Oncology Group (SWO

A. Nademanee, R. Fisher, M. Leblanc, 2006, Blood.

PET-Adapted Nivolumab or Nivolumab Plus ICE As First Salvage Therapy in Relapsed or Refractory Hodgkin Lymphoma

A. Nademanee, L. Kwak, S. Rosen, 2019, Blood.

Use of radioimmunotherapy in stem cell transplantation and posttransplantation: focus on yttrium 90 ibritumomab tiuxetan.

A. Nademanee, J. Winter, I. Flinn, 2007, Current stem cell research & therapy.

Hematopoietic Stem Cell Transplantation (HSCT) using Umbilical Cord Blood units (UCB) not depleted of red blood cells prior to cryopreservation

A. Nademanee, D. Gjertson, R. Chow, 2006 .

Double Expressing (MYC/BCL2) and Double-Hit Diffuse Large B-Cell Lymphomas Have Inferior Survival Following Autologous Stem Cell Transplantation

D. Weisenburger, A. LaCasce, A. Nademanee, 2015 .

Outcomes with Autologous (Auto) and Allogeneic (Allo) Stem Cell Transplantation (SCT) for Relapsed/Refractory Follicular Lymphoma (FL) in the Post-Rituximab Era: A Comparative Analysis From the National Comprehensive Cancer Network (NCCN) Non-Hodgkin's Lymphoma (NHL) Outcomes Database Project,

L. Gordon, A. LaCasce, A. Vanderplas, 2011 .

Efficacy of just‐in‐time plerixafor rescue for Hodgkin's lymphoma patients with poor peripheral blood stem cell mobilization

A. Nademanee, Shan Yuan, Shirong Wang, 2014, Transfusion.

Clinical Trials and Observations

A. Nademanee, R. Fisher, J. Unger, 2008 .

Ganciclovir/immunoglobulin combination therapy for the treatment of human cytomegalovirus-associated interstitial pneumonia in bone marrow allograft recipients.

A. Nademanee, J. Zaia, S. Forman, 1988, Transplantation.

Allogeneic bone marrow transplantation for high-risk acute lymphoblastic leukemia during first complete remission.

A. Nademanee, M. Amylon, R. Hoppe, 1991, Blood.

Solid cancers after bone marrow transplantation.

A. Nademanee, J. Niland, A. Krishnan, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors.

A. Nademanee, J. Niland, A. Krishnan, 2000, Blood.

NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017.

J. Byrd, R. Advani, J. Vose, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

Tacrolimus and Sirolimus as GVHD Prophylaxis for HLA-MRD Allogeneic HCT Conditioned with 3 Regimens: Toxicity and Efficacy in 70 Patients.

A. Nademanee, S. Forman, D. Senitzer, 2006 .

Acute leukemic manifestation of recurrent anaplastic large-cell lymphoma 20 years after autologous bone marrow transplantation.

A. Nademanee, K. Gaal, Qin Huang, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High dose therapy and autologous stem cell transplantation for human immunodeficiency virus‐associated non‐Hodgkin lymphoma in the era of highly active antiretroviral therapy

A. Nademanee, A. Krishnan, J. Zaia, 2000, Cancer.

Non-Hodgkin's lymphomas.

J. Byrd, R. Advani, J. Vose, 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia.

A. Nademanee, M. Horowitz, S. Spellman, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Remission of refractory Sezary syndrome after bone marrow transplantation from a matched unrelated donor.

A. Nademanee, D. Arber, S. Forman, 1999, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Bone marrow transplantation for acute nonlymphoblastic leukemia during first complete remission. An analysis of prognostic factors.

A. Nademanee, D. Findley, R. Krance, 1987, Transplantation.

Updated Results of High-Dose Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan with High-Dose Etoposide (VP-16) and Cyclophosphamide (CY) Followed by Autologous Hematopoietic Cell Transplant (AHSCT) for Poor-Risk or Refractory B-Cell Non-Hodgkin’s Lymphoma.

A. Nademanee, A. Krishnan, S. Forman, 2007 .